You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Nizatidine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for nizatidine and what is the scope of patent protection?

Nizatidine is the generic ingredient in three branded drugs marketed by Smithkline Beecham, Ani Pharms, Apotex Inc, Dr Reddys Labs Ltd, Epic Pharma Llc, Glenmark Pharms Inc, Mylan Pharms Inc, Norvium Bioscience, Watson Labs, Braintree, Amneal Pharms, and Haleon Us Holdings, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for nizatidine. Four suppliers are listed for this compound.

Summary for nizatidine
Drug Prices for nizatidine

See drug prices for nizatidine

Recent Clinical Trials for nizatidine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daewoong Pharmaceutical Co. LTD.Phase 4
National Center for Research Resources (NCRR)Phase 1
Adil BharuchaPhase 1

See all nizatidine clinical trials

Pharmacology for nizatidine
Medical Subject Heading (MeSH) Categories for nizatidine
Paragraph IV (Patent) Challenges for NIZATIDINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AXID Oral Solution nizatidine 15 mg/mL 021494 1 2008-05-14

US Patents and Regulatory Information for nizatidine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc NIZATIDINE nizatidine CAPSULE;ORAL 075934-001 Jul 9, 2002 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Glenmark Pharms Inc NIZATIDINE nizatidine CAPSULE;ORAL 090618-002 Jul 15, 2011 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ani Pharms NIZATIDINE nizatidine CAPSULE;ORAL 075668-001 Sep 12, 2002 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Braintree AXID nizatidine SOLUTION;ORAL 021494-001 May 25, 2004 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Glenmark Pharms Inc NIZATIDINE nizatidine CAPSULE;ORAL 090618-001 Jul 15, 2011 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for nizatidine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-002 Apr 12, 1988 4,382,090 ⤷  Subscribe
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-001 Apr 12, 1988 4,375,547 ⤷  Subscribe
Braintree AXID nizatidine SOLUTION;ORAL 021494-001 May 25, 2004 6,930,119 ⤷  Subscribe
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-002 Apr 12, 1988 4,760,075 ⤷  Subscribe
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-002 Apr 12, 1988 4,375,547 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Nizatidine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Nizatidine

Introduction to Nizatidine

Nizatidine is a histamine H2 receptor antagonist, initially developed by Eli Lilly & Co., and is widely used to treat various gastrointestinal disorders such as peptic ulcers, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD)[2].

Market Size and Forecast

The global market for nizatidine is experiencing significant growth. As of 2021, the market value was estimated at approximately USD 5.1 billion, and it is projected to reach USD 12.2 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 9% during the 2021-2031 period[1].

Another forecast suggests that the nizatidine market was valued at USD 5.40 billion in 2022 and is expected to reach USD 10.85 billion by 2030, growing at a CAGR of 7.93% from 2023 to 2030[4].

Key Drivers of Market Growth

Rising Prevalence of Gastrointestinal Disorders

The increasing prevalence of gastrointestinal disorders such as peptic ulcers, gastric ulcers, and GERD is a major driver of the nizatidine market. For instance, peptic ulcer disease affects approximately four million people globally each year, with a lifetime prevalence of 5-10% in the general population[4].

Aging Population

The aging population is more susceptible to gastrointestinal disorders, which further fuels the demand for nizatidine. The growing elderly population, particularly in regions like North America, contributes significantly to the market growth[4].

Research and Development

Ongoing research and development activities aimed at improving the formulation and efficacy of nizatidine also drive market growth. For example, nizatidine is being investigated for its anti-inflammatory effects and potential use in developing anti-viral drugs, including those to counter the COVID-19 pandemic[1].

Market Segmentation

By Type

The nizatidine market is segmented into nizatidine capsules, nizatidine tablets, and other types. Nizatidine capsules are expected to witness huge demand, growing at a CAGR of over 10% from 2021 to 2031. This is due to their faster absorption and quicker onset of action compared to tablets[1][4].

By Distribution Channel

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies currently hold the highest share, ensuring accurate dosing, controlled dispensing, and expert pharmacist support. However, sales through retail and online pharmacies are expanding rapidly, with a CAGR of about 14%, due to the convenience and accessibility they offer[1][4].

Geographical Analysis

North America

North America contributes the highest share to the global nizatidine market, driven by the high prevalence of ulcers and GERD, particularly among the aging population. The region's robust healthcare infrastructure and high healthcare expenditure also play a significant role[4].

India

India is another key market, expected to grow at a CAGR of 8.5% by 2031. India is the world's largest provider of generic medications, and the home market is predicted to grow threefold by 2031, with medicine spending expected to increase by more than 9%[1].

United States

In the U.S., the market is driven by the high incidence of digestive diseases, with over 20 million hospitalizations annually. Companies like Amneal Pharmaceuticals Inc. have been given permission to resume sales of their nizatidine oral solutions, indicating potential future growth. The U.S. market is expected to grow at a CAGR of 7.2% until 2031[1].

Competitive Landscape

The nizatidine market is competitive, with several key players including:

  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Strides Pharma Science
  • Mylan
  • MedChemExpress
  • Weightech (Hunan) Pharmaceutical
  • Hengdian Group
  • Lilly
  • Chongqing Zhien Pharmaceutical
  • Changzhou Sailu Industry[4].

These companies are involved in various strategies such as product benchmarking, SWOT analysis, and innovation to maintain their market position.

Distribution and Sales Channels

While hospital pharmacies remain the primary source of nizatidine, sales through retail and online pharmacies are growing rapidly. The convenience and accessibility offered by these channels are making them increasingly popular among consumers[1][4].

Challenges and Opportunities

Regulatory Approvals

Regulatory approvals play a crucial role in the growth of the nizatidine market. Expedited approvals in regions like India are expected to attract more players into the market, driving growth[1].

Generic Medications

The trend towards generic medications is also a significant factor. States are encouraging the use of lower-cost generic drugs, which can impact the market dynamics of branded nizatidine products[3].

Key Takeaways

  • The global nizatidine market is projected to grow significantly, driven by the rising prevalence of gastrointestinal disorders and the aging population.
  • Nizatidine capsules are expected to dominate the market due to their faster absorption and quicker onset of action.
  • North America and India are key regions driving market growth.
  • The market is highly competitive, with several major pharmaceutical companies involved.
  • Sales through retail and online pharmacies are expanding rapidly due to convenience and accessibility.

FAQs

1. What is the primary use of nizatidine?

Nizatidine is primarily used to treat gastrointestinal disorders such as peptic ulcers, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD) by acting as an H2 receptor antagonist to reduce stomach acid production.

2. What is the projected market size of nizatidine by 2031?

The global market for nizatidine is expected to reach approximately USD 12.2 billion by 2031, growing at a CAGR of 9% from 2021 to 2031[1].

3. Which region is expected to grow the most in the nizatidine market?

India is expected to witness high growth, with the market poised to surge at a CAGR of 8.5% by 2031, driven by its status as the world's largest provider of generic medications and increasing medicine spending[1].

4. What are the key distribution channels for nizatidine?

The key distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. While hospital pharmacies currently hold the highest share, sales through retail and online pharmacies are growing rapidly[1][4].

5. Which companies are major players in the nizatidine market?

Major players include Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Strides Pharma Science, Mylan, MedChemExpress, and others[4].

Cited Sources:

  1. Fact.MR - Nizatidine Market Size, Share, Growth Forecast to 2031
  2. Patsnap Synapse - Nizatidine: Drug Targets, Indications, Patents
  3. Medicaid.gov - National Medicaid Fee-For-Service Drug Utilization Review
  4. Verified Market Research - Nizatidine Market Size, Share, Trends, Opportunities & Forecast

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.